Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AOH1996 in Refractory Solid Tumors
NCT05227326Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Sep 2022
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aoh1996 in solid tumor, osteosarcoma (OS), leiomyosarcoma (LMS) and 4 more, sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 30 days and Dose limiting toxicities at 28 days. Started Sep 2022; status: recruiting.
02
Drugs
aoh1996
03
Conditions
solid tumorosteosarcoma (OS)leiomyosarcoma (LMS)synovial sarcoma (SS)ovarian cancer
Beyond the preview
Go deeper on NCT05227326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227326.